Pharma Industry, Pharma News, Indian Pharmaceutical Company News, International Pharmaceutical Company News update
Analysts see Lupin's acquisition in US positive move but feel benefits may take time

Analysts see it as a good opportunity for Lupin but feel the company may need to wait for say another two years or so for benefits to accrue since they may first need to invest in certain things, putting additional pressure on the company.

 
 
Those within the industry see this as an important development as the study points to the conjugate vaccine being superior to polysaccharide vaccine.
The company which started its Indian operations in 2004 is going to launch some of its latest epilepsy and cancer drugs in India.
The most striking thing about the policy draft is, that it has good policy goals but gives little thought on the road map and challenges in meeting them.
Certain pharma industry leaders point out that the draft of new pharmaceutical policy has been written in an amateurish manner.
 
 
The company will pursue oncology, dermatology and respiratory as  three chosen therapy areas of focus and will straddle the entire value chain of products.
NPPA Chairman Bhupendra Singh said that a similar exercise to identify the price patterns prevailing in medical device sector is underway.
Advertisement